Physician profile
Yaying Wang
NPI 1730737875
$1,316.38
in general payments reported to CMS, 2019-2025
18 companies · $783 in 2025
The $783 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.38 · 2023: $166 · 2024: $353 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $526.66 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $210.22 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Gilead Sciences, INC. | $90.24 | 2023-2025 | Epclusa |
| Exact Sciences Corporation | $85.63 | 2023-2025 | Cologuard Collection Kit |
| Viiv Healthcare Company | $57.90 | 2025 | Apretude |
| Abbvie INC. | $47.59 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $42.10 | 2021-2024 | Farxiga, Airsupra |
| Pfizer INC. | $37.36 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.29 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $31.61 | 2023-2024 | M-M-R II, Gardasil 9, Proquad |
| Amgen INC. | $30.59 | 2024 | Otezla, Repatha |
| Seqirus USA INC | $24.60 | 2024 | Flucelvax, Fluad |
| Otsuka America Pharmaceutical, INC. | $21.66 | 2023 | Rexulti |
| Glaxosmithkline, LLC. | $17.82 | 2023 | Arexvy, Shingrix |
| Mayne Pharma Commercial LLC | $16.13 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $15.72 | 2025 | Dexcom G6 Transmitter |
| Exeltis, USA INC. | $14.14 | 2024 | Slynd |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.12 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yaying Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.